Skip to main content

Table 1 Demographic and Clinical Characteristics of Non-Diabetic controls (ND) and Diabetic Non-Neuropathic Subjects (DNN), as well as Patients with Sensory Polyneuropathy with Hypoesthesia (DShP) or Hyperesthesia (DSHP), and Diabetic Motor Neuropathy (DMN)

From: Neuropathy-specific alterations in a Mexican population of diabetic patients

  ND DNN DShP DSHP DMN
Demographic characteristics N = 375 N = 26 N = 121 N = 55 N = 41
 Age (years) 56 (49–63) bc 50 (42–59) c 58 (52–63) ab 56 (52–61) abc 61 (55–65) a
 Female gender (%) 75 (281/375) a 69 (18/26) ab 63 (76/121) b 62 (34/55) ab 56 (23/41) b
Medical history
 Duration of Diabetes (years) - 4 (2–8) b 8 (3–13) ab 10 (4–15) a 13 (5–18) a
 Hypertension (%) - 12 (3/26) a 21 (25/121) a 24 (13/55) a 27 (11/41) a
Medical treatment
 Oral Hypoglycemic Drugs (%) - 96 (25/26) ab 93 (112/121) a 89 (49/55) ab 78 (32/41) b
 Insulin treatment (%) - 8 (2/26) b 17 (21/121) b 27 (15/55) ab 34 (14/41) a
 PPAR-α/γ Activators pioglitazone or bezafibrate (%) - 42 (11/26) a 20 (24/121) b 16 (9/55) b 22 (9/41) ab
 HMGCoA reductase Inhibitors (%) - 23 (6/26) a 12 (15/121) a 11 (6/55) a 15 (6/41) a
  1. Different letters indicate statistical differences among groups with a p < 0.05, using a Kruskal-Wallis test with a Dunn post test. Data expressed as percentages were analyzed using a Chi-squared test with Yate’s correction for continuity on 2 × 2 contingency tables. Data are represented as median (25th – 75th percentiles of the distribution), except for percentages, which are represented as percentage (number of patients fulfilling the condition/sample size, N)